MRD validated as a surrogate endpoint for survival in AML

Zamtocabtagene autoleucel improves event-free survival vs standard of care in second-line r/r LBCL

Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas

Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab

Empowering cancer care in Africa

Do all hormone sensitive prostate cancers need triplet therapy?

ESMO 2025: Highlights and analysis

ctDNA-guided adjuvant atezolizumab improves OS in MIBC

ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable outcomes in stage III colon cancer

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC